Message

From: Weiner, Matthew [weiner.matthew@epa.gov]
Sent: 1/20/2022 4:39:17 PM
To: Welch, Kara [welch.kara@epa.gov]; Ortiz, Nina [Ortiz.Nina@epa.gov]; Kirk, Cassandra [kirk.cassandra@epa.gov]; Mendelsohn, Mike [Mendelsohn.Mike@epa.gov]; Reynolds, Alan [Reynolds.Alan@epa.gov]; Milewski, Elizabeth [Milewski.Elizabeth@epa.gov]; Striegel, Wiebke [Striegel.Wiebke@epa.gov]; Piombino, Michael [Piombino.Michael@epa.gov]

from the 75 day letter response: Oxitec has carried out fluorescent validation by PCR (40 fluorescent and 40 non-fluorescent individuals) once at the start of the EUP, for each technical operator who carried out fluorescence screening according to GL-SOP-00052, as described in the Section G protocol in Section 4.6.5.1. Oxitec intends to carry out the same one-time fluorescent validation by PCR for all new technical operators carrying out fluorescence screening, whether based in Florida or in California.
The requirement to test 150 non-fluorescent females reared from ovitraps as described in the EUP issuance letter (30 Apr 2020) is carried out once per month, and will continue throughout the transgene persistence measurements after the cessation of releases, noting that the total number of non-fluorescent females available for screening after the end of releases may fall below 150 per month as this is likely to coincide with the low mosquito season in both trial locations. In this case, Oxitec would test as many non-fluorescent females as were available, up to 150 in total per month.